Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etoposide/Cisplatin vs Irinotecan/Cisplatin in GI NET G3
NCT03963193Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial in gastrointestinal neuroendocrine tumor comparing Etoposide plus Cisplatin with Irinotecan plus Cisplatin (2 arms). Primary endpoints: Objective Response Rate up to 2 years and Progression-free Survival up to 2 years. Status: unknown.
02
Drugs
etoposideirinotecan
03
Conditions
gastrointestinal neuroendocrine tumor
Beyond the preview
Go deeper on NCT03963193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03963193.